AxoGen to Expand Enrollment of Phase 3 Study of Avance Nerve Graft

AxoGen (AXGN) said Monday that it has completed the planned interim analysis for its phase 3 RECON study, which will support the submission of a Biologic License Application (BLA) to the Food and Drug Administration for for its Avance Nerve Graft. Based on the results of the interim analysis, the study’s independent biostatistician recommended continuation of the study with a […]